Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter, Chatham in Hemophilia Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Baxter, Chatham in Hemophilia Pact

To collaborate on next-gen gene therapy technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter International has entered into an exclusive global agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical (AskBio), for the development and commercialization of potential treatments for hemophilia B using Chatham’s gene therapy technology.

Baxter paid $25 million upfront for the development and advancement of the program through early clinical trials, and may make additional payments based on certain development and commercial milestones.

Baxter will use Chatham’s Biological Nano Particles (BNP), an advanced recombinant adeno-associated virus (rAAV) based gene therapy technology that has shown potential therapeutic benefit in early clinical studies. The agreement involves the next generation of this gene therapy technology, which Baxter and Chatham will investigate through U.S.-based hemophilia B clinical trials. Baxter has obtained global rights for the marketing and commercialization of the new treatment.

“This collaboration demonstrates Baxter’s ongoing commitment to scientific innovation in advancing treatment options for patients living with hemophilia. This initiative complements Baxter’s extensive hemophilia portfolio and helps to address unmet needs of hemophilia patients,” said Ludwig Hantson, Ph.D., president of Baxter’s BioScience business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics